• Subscribe
  • Magazines
  • About
  • Contact
  • Advertise
Wednesday 27 August 2025
  • zh-hant 中文
  • ja 日本語
  • en English
IAG
Advertisement
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
    • Africa
    • Australia
    • Cambodia
    • China
    • CNMI
    • Europe
    • Hong Kong
    • India
    • Japan
    • Laos
    • Latin America
    • Malaysia
    • Macau
    • Nepal
    • New Zealand
    • North America
    • North Korea
    • Philippines
    • Russia
    • Singapore
    • South Korea
    • Sri Lanka
    • Thailand
    • UAE
    • Vietnam
  • Events
  • Contributors
  • SUBSCRIBE FREE
  • 中文
  • 日本語
No Result
View All Result
IAG
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
    • Africa
    • Australia
    • Cambodia
    • China
    • CNMI
    • Europe
    • Hong Kong
    • India
    • Japan
    • Laos
    • Latin America
    • Malaysia
    • Macau
    • Nepal
    • New Zealand
    • North America
    • North Korea
    • Philippines
    • Russia
    • Singapore
    • South Korea
    • Sri Lanka
    • Thailand
    • UAE
    • Vietnam
  • Events
  • Contributors
  • SUBSCRIBE FREE
  • 中文
  • 日本語
No Result
View All Result
IAG
No Result
View All Result

COVID-19 vaccine could be available by October after “world first” facility in Beijing granted production approval

Newsdesk by Newsdesk
Sun 9 Aug 2020 at 11:09
COVID-19 vaccine could be available by October after “world first” facility in Beijing granted production approval
327
SHARES
4.5k
VIEWS
Print Friendly, PDF & Email

China could make available the world’s first COVID-19 vaccine as early as October after the state-run China National Biotec Group (CNBG) announced that a vaccine production facility passed national examination.

According to a report in The Global Times, the facility, located in Beijing, was granted a production certificate following a recent thorough biosecurity examination, meaning it has now been approved to start large scale production once a COVID-19 vaccine is ready. It is described as the “first and largest of its kind” in the world and has the ability to produce 220 million doses of vaccine annually.

Experts now believe the first doses could be produced and made available as early as October give that a number of domestically made candidate vaccines have already entered Phase III trials.

Among them is a vaccine developed by Chinese pharmaceutical company Sinopharm, which is currently testing its candidate on 15,000 volunteers in the United Arab Emirates and preparing to launch a similar trial in Brazil.

Germany’s BioNTech, working in partnership with Shanghai Fosun Pharmaceutical, announced last week that it is has dosed 72 trial participants with a vaccine using mRNA technology – a method which prompts the human body to create its own infection-fighting medicine.

As reported extensively by Inside Asian Gaming last week, a team working out of the Faculty of Medicine at Macau University of Science and Technology (MUST), in collaboration with scientists from mainland China and Hong Kong, have made their own potentially game changing breakthrough, announcing that a vaccine developed using certain residues found in the Spike protein receptor-binding domain (S-RBD) – which is what the COVID-19 virus uses to engage with the cells of the host and cause infection – induced a “potent functional antibody response” in immunized mice, rabbits and monkeys.

These antibodies effectively blocked S-RBD from binding with the host cell receptor as it does in cases of infection, therefore neutralizing the virus during laboratory studies.

Any vaccine produced out of the newly approved Beijing facility would first be used locally, primarily on medical staff and those working at border checkpoints, however the timeline is notable given that most candidate vaccines have targeted early 2021 for release.

“It is possible that China could have a COVID-19 vaccine as early as the end of October as some domestically made COVID-19 vaccines have entered phase three clinical trials and need about a month to observe their effects on samples,” Shanghai-based vaccine researcher Tao Lina told The Global Times.

There are reportedly 13 Chinese companies currently working on the development of COVID-19 vaccines of which nine have been approved for clinical trials.

RelatedPosts

Singapore’s Changi Airport now Asia’s busiest airport as Hong Kong falls further behind

Singapore’s Changi Airport says passenger traffic from China up almost 16% in 2Q25

Wed 23 Jul 2025 at 05:55
Starr Xian: Human Factor

China’s GDP grows 5.3% in first half of 2025, in line with expectations

Tue 15 Jul 2025 at 12:30
Macau ranks first in China Tourism Academy’s “2024 Chinese Travellers Outbound Satisfaction Top 10 Destinations”

Macau ranks first in China Tourism Academy’s “2024 Chinese Travellers Outbound Satisfaction Top 10 Destinations”

Sun 29 Jun 2025 at 09:57
Falling Thailand visitor numbers linked to safety concerns as IR operators say it’s time to reboot tourism offering

Falling Thailand visitor numbers linked to safety concerns as IR operators say it’s time to reboot tourism offering

Thu 12 Jun 2025 at 16:40
Load More
Tags: ChinaChina National Biotec Groupcovid-19Faculty of Medicine at Macau University of Science and TechnologyProduction facilityThe Global TimesVaccination
Share218Share13
Newsdesk

Newsdesk

The IAG Newsdesk team comprises some of the most experienced journalists in the Asian gaming industry. Offering a broad range of expertise, their decades of combined know-how spans multiple countries across a variety of topics.

Current Issue

Editorial – Better late than never

Editorial – Better late than never

by Ben Blaschke
Thu 31 Jul 2025 at 07:13

Inside Asian Gaming has in recent weeks been hearing increasing chatter around a possible move by Vietnamese authorities to introduce...

Angel’s Yasushi Shigeta

Angel’s Yasushi Shigeta

by Ben Blaschke
Thu 31 Jul 2025 at 07:08

Yasushi Shigeta, Chairman and owner of one of the world’s largest gaming industry suppliers, Angel Group, sits down with Inside...

The Magic Number

The Magic Number

by David Bonnet
Thu 31 Jul 2025 at 06:41

In this in-depth deep dive into the evolution of the Asian gaming landscape, David Bonnet argues that many regional jurisdictions...

Rashid Suliman – A road well traveled

Rashid Suliman – A road well traveled

by Ben Blaschke
Thu 31 Jul 2025 at 02:45

Rashid Suliman, Vice President of Global Gaming Asia-Pacific for casino solutions provider TransAct Technologies, provides some insight into his unique...

Evolution Asia
Your browser does not support HTML5 video.
Aristocrat
GLI
Nustar
SABA
Mindslot
Solaire
Hann
Tecnet
HKUST
NWR

Related Posts

Macau GGR down 62% year-on-year to MOP$2.48 billion in June

Morgan Stanley: Macau gaming stocks likely set for re-rating given recent dividend payouts

by Ben Blaschke
Tue 26 Aug 2025 at 12:59

Macau gaming stocks look set for a re-rating given a recent spate of dividend declarations and growing bullishness on the sector, according to investment bank Morgan Stanley. In a recent note in which they outlined their expectation for a 15%...

Sons of NagaCorp founder Chen Lip Keong join Forbes list of Malaysia’s richest

Surging mass market sees NagaCorp gaming revenues, profit enjoy double-digit growth in 1H25

by Ben Blaschke
Tue 26 Aug 2025 at 05:30

Hong Kong-listed NagaCorp has credited the impressive growth of the mass market segment at its Cambodian integrated resort NagaWorld for substantial improvement in both its gross gaming revenues (GGR) and profitability in the first six months of 2025. NagaWorld booked...

MGS returns to Macau today with first live in-person show in four years

Galaxy looking to maintain events focus as Galaxy Arena extends partnership with TMElive by three years

by Newsdesk
Tue 26 Aug 2025 at 04:59

Galaxy Entertainment Group’s Galaxy Arena has renewed by a further three years its strategic partnership with live events company TMElive, aiming to further build on the high-profile array of entertainment offerings that have contributed to Macau’s post-pandemic recovery. In its...

Flutter stops India real-money gaming operations, bemoans lack of industry consultation

Flutter stops India real-money gaming operations, bemoans lack of industry consultation

by Ben Blaschke
Tue 26 Aug 2025 at 04:00

British gaming giant Flutter Entertainment says it expects to forfeit around US$100 million in revenue and US$25 million in Adjusted EBITDA after stopping its real-money gaming operations in India following the sudden passage of the Promotion and Regulation of Online...

Your browser does not support the video tag.


IAG

© 2005-2025
Inside Asian Gaming.
All rights reserved.

  • SUBSCRIBE FREE
  • NEWSFEED
  • MAG ARTICLES
  • VIDEO
  • OPINION
  • TAGS
  • REGIONAL
  • EVENTS
  • CONSULTING
  • CONTRIBUTORS
  • MAGAZINES
  • ABOUT
  • CONTACT
  • ADVERTISE
  • 中文
  • 日本語

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • 中文
  • 日本語
  • Subscribe
  • Newsfeed
  • Mag Articles
  • Video
  • Opinion
  • Tags
  • Regional
  • Events
  • Contributors
  • Magazines
  • Advertise
  • Contact
  • About
  • Home for G2E Asia

© 2005-2025
Inside Asian Gaming.
All rights reserved.

  • 中文
  • English
  • 日本語